Science Behind Genacol
At Genacol, we care about our customers’ joint health and well-being. This is why we have been committed for more than 20 years to a quest for excellence driven by a strong desire for technical and scientific innovation.
A Unique Patented Technology
Thanks to Genacol’s patented enzymatic hydrolysis technology, the AminoLock® Sequence Technology, we obtain ultra-hydrolyzed collagen from a bovine source: AminoLock® Collagen. This unique collagen peptide has the lowest molecular weight in the world at less than 1 kilodalton (kDa) and is specifically designed to reduce joint pain associated with osteoarthritis. CA Patent Number 2950096 | US Patent Number 11.040.081
McGill Research: AminoLock® Collagen Bioavailability
Collaborative Research results
This collaborative research project with McGill University has demonstrated better bioavailability of AminoLock® Collagen. In addition, it showed that several peptides important for joint health are better absorbed and metabolized than generic collagen. These essential peptides provided by our proprietary ingredient have been measured, along with their known joint health benefits, confirming that Genacol® AminoLock® Collagen is indeed different and unique. 1. Larder, C.E.; Iskandar, M.M.; Sabally, K.; Kubow, S. Complementary and efficient methods for di- and tri-peptide analysis and amino acid quantification from simulated gastrointestinal digestion of collagen hydrolysate. LWT 2022, 155, 112880, doi:https://doi.org/10.1016/j.lwt.2021.112880. 2.Larder, C.E.; Iskandar, M.M.; Kubow, S. Assessment of Bioavailability after In Vitro Digestion and First Pass Metabolism of Bioactive Peptides from Collagen Hydrolysates. Current Issues in Molecular Biology 2021, 43, 1592-1605, doi:10.3390/cimb43030113.
Bruyère Clinical Study: Effectiveness on Joint Pain
Clinical Study Result
After six months of treatment, the results showed a significant increase in the proportion of patients reporting a notable reduction in joint pain when they consumed Genacol AminoLock® Collagen compared to patients on placebo. Bruyère O, et al. Effect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo-controlled study. Complement Ther Med (2012).​
The first study was a multicenter randomized placebo-controlled trial carried out in Belgium by world-renowned researchers in the field of osteoarthritis (10).
Patients suffered from joint pain in various areas: upper body (shoulder, elbow, wrist), lower back or lower body (hip, knee). Over 140 patients were randomly assigned to receive either 1200 mg of Genacol® AminoLock® Collagen or a placebo. The study was well balanced (baseline patient characteristics) and of excellent quality. The authors used a visual analog scale (VAS), the Gold Standard reference test, for the subjective assessment of pain. The VAS scale is notably used to demonstrate the clinical efficacy of analgesic drugs. It is recognized by regulatory agencies such as the US Federal Drug Agency (FDA) and the Canadian Therapeutic Products Directorate (TPD).
Parm Clinical Study: Improving Joint Space
Clinical Study Result
After six months of treatment, the results of this clinical study indicate that Genacol® AminoLock Collagen may not only reduce pain and improve knee function in patients with osteoarthritis but also prevent joint space degradation. Maria Lourdes R. Bernardo and Alfredo C. Azarcon, Jr. Effects of Oral Collagen Treatment on the Media Knee Joint Space and Functional Outcome among Veterans Memorial Medical Center Patients Diagnosed with Osteoarthritis of the Knee (2012).
A second clinical study was carried out in a Veterans Hospital Center in the Philippines; this time, the study focused on patients suffering from knee osteoarthritis (12). A total of 113 patients were randomly assigned to receive either a daily dose of 1200 mg of Genacol® AminoLock® Collagen or a daily dose of 200 mg of aceclofenac, a standard non-steroidal anti-inflammatory drug (NSAID). The authors used the Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC). The latter is often considered the reference test for knee osteoarthritis since it assesses pain and joint function in several daily situations of rest and activity (13).
Clinical Study Result
After 6 months of treatment, this clinical study showed that taking AminoLock Collagen combined with an exercise program reduced pain, improved general functional status and caused changes to intra-articular and periarticular structures compared to patients on placebo. Chan, R., & De Los Reyes, M. F. Effect of Collagen Hydrolysate as an adjuvant treatment to Exercise for Knee Osteoarthritis (2016).
